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Background: Synergistic transcriptional activation by different stimuli has been reported along with a diverse array
of mechanisms, but the full scope of these mechanisms has yet to be elucidated.
Results: We present a detailed investigation of hypoxia-inducible factor (HIF) 1 dependent gene expression in
endothelial cells which suggests the importance of crosstalk between the peroxisome proliferator-activated receptor
(PPAR) β/δ and HIF signaling axes. A migration assay shows a synergistic interaction between these two stimuli,
and we identify angiopoietin-like 4 (ANGPTL4) as a common target gene by using a combination of microarray and
ChIP-seq analysis. We profile changes of histone marks at enhancers under hypoxia, PPARβ/δ agonist and dual
stimulations and these suggest that the spatial proximity of two response elements is the principal cause of the
synergistic transcription induction. A newly developed quantitative chromosome conformation capture assay shows
the quantitative change of the frequency of proximity of the two response elements.
Conclusions: To the best of our knowledge, this is the first report that two different transcription factors cooperate
in transcriptional regulation in a synergistic fashion through conformational change of their common target genes.Background
The vascular system sits at the center of oxygen delivery in
mammals, and its inner layer endothelial cells play an es-
sential role in network formation. In addition to the
physiological angiogenesis that occurs in wound healing
and during aerobic exercise, hypoxia is involved in various
pathological conditions, for example, cardiovascular dis-
ease, diabetic complications, inflammatory diseases and
cancer. Poor perfusion of vital organs, including the brain,
heart, liver and kidney, can result in hypoxia and critical* Correspondence: ywada-tky@umin.ac.jp
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reproduction in any medium, provided the orloss of function. In the core of solid tumors, oxygen de-
mand surpasses the capacity of feeding arteries and the
cells are exposed to hypoxia, sometimes with deleterious
effects on the progress of the disease. In both contexts, the
endothelium is the first cell layer that senses hypoxia as
well as changes in hemodynamic forces and blood-borne
signals, and this evokes the first step in response to hyp-
oxia, namely angiogenesis [1]. Responding to a demand for
more oxygen, endothelial cells migrate and proliferate to
form solid endothelial cell sprouts into the stromal space
through the induction of a series of gene transcriptional
events required for an increased oxygen supply [2].
In the gene regulation that takes place under hypoxia,
hypoxia-inducible factor (HIF)1 is regarded as one of the
master gene regulators [3] and we previously reportedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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cells [4]. Angiogenesis is enhanced by HIF, and it is fur-
ther orchestrated by various other angiogenic factors, in-
cluding vascular endothelial growth factor (VEGF) [5],
basic fibroblast growth factor (bFGF) [6], angiopoietins
and angiopoietin-like (ANGPTL) proteins [7]. In addition
to HIF1, another transcription factor (TF), peroxisome
proliferator-activated receptors (PPAR)β/δ is reported to
participate in angiogenesis [8,9]. PPARs are known to be
important in the regulation of numerous biological pro-
cesses, including lipid metabolism [10], adipocyte differenti-
ation [11,12], cell proliferation [12] and inflammation [13].
To date, three PPAR isotypes have been identified, PPARα,
PPARβ/δ and PPARγ. PPARα and PPARγ play a crucial role
in lipid metabolism [10], and reports from various groups,
including ours, have shown that PPARβ/δ, as well as the
other isotypes, also regulate lipid metabolism [14]. In a
recent study it was reported that the PPARβ/δ agonist
GW501516 stimulated human umbilical vein endothelial
cell (HUVECs) proliferation dose-dependently [9], pro-
moted endothelial tube formation, and increased angi-
ogenesis [8]. Another PPARβ/δ agonist, GW0742, or
muscle-specific overexpression of PPARβ/δ, also promoted
angiogenesis in mouse skeletal muscle [15]. Additional evi-
dence further suggested that PPARβ/δ is one of the im-
portant TFs participating in the angiogenic network in
endothelial cells [16,17]. These lines of evidence are
strongly suggestive of a role for PPARβ/δ in angiogenesis.
Although several key TFs have been shown to be in-
volved in angiogenesis, the detailed underlying hierarch-
ical or mutual interaction of multiple cascades is only
partially understood [16]. To dissect the molecular mech-
anism of crosstalk in angiogenesis, we selected two im-
portant angiogenic stimuli, hypoxia and PPARβ/δ agonist
stimulation, and investigated the molecular mechanism by
which these two signals in concert are able to enhance a
common angiogenesis-related target gene.
In this study, we are focusing on the new molecular
mechanism where conformational change could contribute
to the co-operative transcriptional regulation of a common
target by two different TFs. It was previously reported
that synergistic transcription could be achieved by different
TFs through enhanceosomes [18,19], which are complexes
made from proteins binding to regulatory elements of
genes. Apart from the enhansceosome concept, which em-
phasizes the diversity of TF specificity, our findings on syn-
ergistic transcription suggest that chromatin structural
changes are inseparable from the transcription machinery.
Results
Endothelial cell migration is synergistically enhanced by
hypoxic and PPARβ/δ agonist stimuli
To confirm the physiological effect of hypoxia and the
PPARβ/δ agonists, and to evaluate the physiologicalcrosstalk of these angiogenic stimuli in endothelial cells,
we applied PPARβ/δ and hypoxia to HUVECs and stud-
ied the effect on cellular migration function by using a
monolayer-wound healing assay. Figure 1A shows the
distribution of the cells before and after the stimuli.
Quantification of the endothelial cell migratory area (the
red area in Figure 1A) is shown in Figure 1B. To avoid
the effect of VEGF in the media, the assay was per-
formed using endothelial culture media without any
growth factors or fetal bovine serum (FBS). PPARβ/δ
and hypoxia individually tended to be associated with
greater recovery in HUVECS than normoxia and DMSO,
but this was not statistically significant. However, simul-
taneous application of both stimuli resulted in a signifi-
cant increase in migration of endothelial cells compared
to untreated control. This finding suggested that this ex-
perimental motif could be applied to elucidate the syner-
gistic activation that is exerted through PPARβ/δ and
HIF1α in endothelial cell function. Therefore, we fo-
cused on dissecting the molecular mechanism under-
lying the synergistic effect of the two stimuli.
Genome-wide analysis of PPARβ/δ and/or hypoxia-
induced genes in endothelial cells identified ANGPTL4 as
the common target gene
To estimate the possible interaction of the PPARβ/δ and
HIF1α signaling pathways in a more comprehensive man-
ner, we performed transcriptome analysis using microar-
rays after 24 hours of treatment with a PPARβ/δ-selective
agonist (GW501516, 100 nM) and/or hypoxic (1% O2)
stimulation. After normalization and filtering, gene ex-
pression change against the normoxia-DMSO sample was
calculated. A scatter plot of normalized intensity values of
all genes under two conditions is shown in Figure S1A,B
in Additional file 1. The PPARβ/δ agonist-induced genes
(Figure S1A in Additional file 1) were compared with the
hypoxia-induced genes (Figure S1B in Additional file 1).
In general, the number of genes induced by hypoxia
was much larger than that induced by the PPARβ/δ
agonist. To extract the genes responsive to either of the
stimuli, genes that had a fold change ≥2.0 were selected;
288 genes remained. Hierarchical cluster analysis was per-
formed on these, and the genes were classified into three
clusters (Figure 2A; Figure S2 in Additional file 1). Genes
that exhibited induction under hypoxia are in cluster 1
(Figure 2A; Figure S2 in Additional file 1). This cluster
was then subclustered into four conditions (cluster 1-1
to 1-4), and the genes that also exhibited up-regulation
by the PPARβ/δ agonist were classified into cluster 1-4
(Figure S2 in Additional file 1). Likewise, the genes in-
duced by the PPARβ/δ agonist, but not hypoxia, were
placed into cluster 2 (Figure 2A; Figure S2 in Additional
file 1). As illustrated by the Venn diagram in Figure 2B,




































Figure 1 Endothelial cell migration is synergistically enhanced by hypoxia and the PPARβ/δ agonist. (A) Images acquired for each
stimulus at 0 hour and 8 hours. HUVECs were treated with the PPARβ/δ agonist (GW501516 100 nM) and/or hypoxia (1% O2) for 8 hours. The
vertical lines indicate the edge of the scratch and the red colored regions at 8 hours show the cell migratory area. Representative images are
shown. (B) Quantification of the area of endothelial cell migration. The area colored in red (Figure 1A) was measured and the size relative to
the untreated condition is indicated. Data (mean ± standard deviation) are representative of three independent experiments with similar results.
*P < 0.05 compared with the untreated condition.
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3 genes (fold change ≥1.5). As shown in Table S1 in
Additional file 2, the overlapped genes were angiopoietin-
like 4 (ANGPTL4), arrestin domain-containing 4 (ARRDC4)
and leucine rich adaptor protein 1-like (LURAP1L),
exhibiting 35.3-, 2.5-, 2.2-fold induction under PPARβ/δ
agonist treatment and hypoxia compared to no stimula-
tion, respectively (Table S1 in Additional file 2). All of
these three genes were placed in cluster 1-4 (Figure 2A,
right upper panel).
Genes (fold change ≥1.5, shown in the Venn diagram in
Figure 2B) up-regulated by the PPARβ/δ agonist are listed
in Table S1 in Additional file 2, and the gene most highly
induced by the PPARβ/δ agonist was also ANGPTL4,
which displayed a 7.0-fold induction compared with ve-
hicle treatment. The genes induced by the PPARβ/δ agon-
ist but not hypoxia were included in cluster 2 (Figure 2A,
the lower right panel). In addition, ANGPTL4 was the
gene most highly induced by hypoxia, having a 20.1-fold
induction compared to normoxia (Tables S1 and S2 in
Additional file 2). A scatter plot of the fold change values
induced by the PPARβ/δ agonist or hypoxia compared
with no treatment is shown in Figure S3 in Additional
file 1, again showing that no other genes responded to
the same level as ANGPTL4 under the treatments. Up-
regulation of ANGPTL4 by PPARβ/δ agonist treatment
and hypoxic stimulation were confirmed by quantitative
RT-PCR (qRT-PCR), with the result showing synergistic
activation (Figure 2C). ANGPLT4 transcription was mea-
sured by amplifying nascent transcript with primers rec-
ognizing intron-exon junctions (Figure S4 in Additional
file 1) and similar results were obtained (the primers
for qRT-PCR are shown in Table S3A in Additional
file 2). Western blotting indicated that ANGPTL4 wasalso synergistically generated by the dual stimulation
(Figure S5 in Additional file 1). Increased amounts of
recombinant ANGPTL4 protein were confirmed to enhance
migration of endothelial cells (Figure S6 in Additional
file 1). Taking these data into account, we focused on
ANGPTL4 as a key motif in the elucidation of the mo-
lecular crosstalk mechanism.
Whole genome analysis of PPARβ/δ and HIF1α binding
sites in endothelium confirmed ANGPTL4 as the common
target gene
To extract the genes that are directly regulated by PPARβ/
δ, we carried out chromatin immunoprecipitation (ChIP)
using a PPARβ/δ antibody in HUVECs treated with
PPARβ/δ agonist stimulation for 24 hours, followed by
deep sequencing (ChIP-seq). In total 38,936,258 reads
were aligned and 77.6% of the total reads were aligned
uniquely to the non-repeating human genomic sequence.
Next, we calculated the enrichment of the PPARβ/δ
ChIP DNA fragments compared with the input, and de-
termined the significant PPARβ/δ binding sites accord-
ing to the QuEST algorithm [20]. In total, 364 binding
regions were identified as PPARβ/δ enrichment sites under
PPARβ/δ agonist treatment (Figure S7A in Additional
file 1). To investigate the correlation of the PPARβ/δ bind-
ing regions and the nearest known transcripts, we divided
the regions into five sections based on the distance from
the transcription start site (TSS) of the corresponding
genes. As shown in Figure S7A in Additional file 1, 82%
were positioned in intergenic regions under PPARβ/δ
agonist treatment, 6% were located upstream (25 kbp to 1
kbp upstream of the TSS), and 3% were located on the





Figure 2 Genome-wide analysis of PPARβ/δ and/or hypoxia-induced genes in endothelial cells identified ANGPTL4 as the common
target gene. (A) Left panel: clustering analysis performed using the selected genes. Right upper panel: genes with their expression profiles
placed into the cluster 1-4, which included the genes that responded to both PPARβ/δ agonist and hypoxia. Right lower panel: genes and their
expression profiles in cluster 2, which contained the genes induced by the PPARβ/δ agonist, but not hypoxia. (B) Venn diagram of the PPARβ/δ
agonist and/or hypoxia-induced genes. Based on microarray analysis, after normalization and filtering, gene expression under PPARβ/δ agonist
(GW501516 100 nM) or hypoxia (1% O2) stimulation (24 hours) in HUVECs was compared with no stimulation (DMSO + normoxia), and then genes
that had a fold change ≥1.5 were selected. (C) Quantitative RT-PCR analysis of ANGPTL4 for both types of stimulation. HUVECs were stimulated
with the PPARβ/δ agonist (GW501516 100 nM) and/or hypoxia (1% O2) for 24 hours. Data (mean ± standard deviation) are representative of two
independent experiments with similar results. *P < 0.001 compared between the indicated conditions.
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formed a motif search of PPARβ/δ binding sites (Figure
S7A in Additional file 1, right panel), and the generated
sequences perfectly matched the known PPAR binding
motifs. The qRT-PCR and ChIP-seq data for representa-
tive genes responsive to PPARβ/δ or hypoxia are shown
in Figure S7B,C in Additional file 1. Pyruvate dehydrogen-
ase kinase, isozyme 4 (PDK4), carnitine palmitoyltransfer-
ase 1A (CPT1A) and solute carrier family 25, member
20 (SLC25A20), all listed in Table S1 in Additional file 2,
are well-known PPARβ/δ target genes. In terms of the
hypoxia-induced genes, the genes expressed more than
two-fold under hypoxia compared with normoxia are shownin Table S2 in Additional file 2. The qRT-PCR and
ChIP-Seq data for three representative genes are shown
in Figure S7B,C in Additional file 1. Vascular endothelial
growth factor (VEGFA), solute carrier family 2, member 1
(SLC2A1) and adenylosuccinate synthase like 1 (ADSSL1)
are hypoxia induced genes, showing 3.3-, 6.5- and 4.3-fold
induction compared with normoxia, respectively (Table S2
in Additional file 2). Using previously obtained data on
HIF1α binding sites, the commonly bound genes were ex-
tracted, and the binding of PPARβ/δ and HIF1α at the
ANGPTL4 locus was confirmed (Figure 3A,C). ChIP-seq
analysis revealed that ANGPTL4 is the only gene bound





Figure 3 ChIP-seq analysis (H3K4me1, H3K4me3, HIF1α, PPARβ/δ, H3K27ac) of the ANGPTL4 gene and construct design for the
reporter assay. The displayed enrichment scores for ChIP-seq were calculated by QuEST and visualized with IGB software (Affymetrix). (A)
ChIP-seq data for H3K4me1, H3K4me3 and HIF1α under normoxia or hypoxia. HUVECs were stimulated with normoxia or hypoxia (1% O2) for
24 hours. The kilobase values show the distance from the TSS of ANGPTL4. (B) Constructs shown in Figure 4 are shown in the frame with their
names. Both the constructs were cloned into a pGL3 vector. The displayed hypoxia response element (HRE) motifs (blue arrows and numbers)
were estimated by MatInspector (Genomatix). The numbers under the constructs show the distance from the TSS of ANGPTL4 (in base pairs).
(C,D) ChIP-seq data for PPARβ/δ (C) and H3K27ac (D) using HUVECs stimulated with the PPARβ/δ agonist (GW501516 100 nM) and/or hypoxia
(1% O2) for 24 hours. (E) Basic information for the analysis. The numbers indicate the location on chromosome 19 using the hg18 build. The
arrows show the location of primers for ChIP-PCR in Figure 4.
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most highly induced by the two different regulators was
ANGPTL4.
ANGPTL4 is regulated by both PPARβ/δ and HIF1α
signaling cascades
To determine whether ANGPTL4 was induced through
PPARβ/δ and HIF1α signaling, we performed a series
of experiments using small interfering RNA (siRNA)
against PPARβ/δ and/or HIF1α. As shown in Figure
S8A,B in Additional file 1, the efficiency of the siRNA-
mediated knockdown of PPARβ/δ was over 80% at the
mRNA level with or without its agonist. The efficiencyof the knockdown of HIF1α was over 90% (Figure S8C,D
in Additional file 1). Almost complete inhibition of
ANGPTL4 induction by the agonists was achieved by
the siRNA against PPARβ/δ (Figure S9A in Additional
file 1). ANGPTL4 mRNA levels were reduced by over
70% under hypoxia using either of the two siRNAs
against HIF1α (Figure S9B in Additional file 1). When
both stimuli were applied, ANGPTL4 mRNA levels were
reduced by over 60% using a combination of si-PPARβ/δ
oligo1 and si-HIF1α oligo 1 (Figure S9C in Additional
file 1). These data confirmed that the up-regulation of
ANGPTL4 by the PPPAβ/δ agonist and/or hypoxia is
dependent on both PPARβ/δ and HIF1α.
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of ANGPTL4
Since ANGPTL4 is downstream of the two transcription
cascades and is commonly activated, we tried to dissect
the molecular mechanism of the dual enhancement.
We therefore set out to identify a functional hypoxia
response element (HRE) in ANGPTL4. HUVECs were
stimulated with hypoxia (1% O2) and incubated for
24 hours, followed by identification of histone modifica-
tions (monomethylated histone 3 lysine 4 (H3K4me1),
trimethylated histone 3 lysine 4 H3K4me3, and acety-
lated histone 3 lysine 27 (H3K27ac)) and HIF1α binding
sites by ChIP-seq. As shown in Figure 3A, no binding of
HIF1α was observed under normoxia in the ANGPTL4
gene locus, but five HIF1α binding sites appeared under
hypoxia. H3K4me3, known as a promoter marker [21],
was only observed for ANGPTL4 under hypoxia, sug-
gesting that the ANGPTL4 locus became activated under
hypoxia. Three out of the five potential HIF1α binding
sites were also accompanied by two markers of enhancer
activity, H3K4me1 [22] and H3K27ac [23-25]. As the
resolution of ChIP-seq is about 100 bp [26], to narrow
the binding locus, HRE motifs were predicted in
both the promoter and intron regions (blue arrows in
Figure 3B) using MatInspector software (Genomatix).
Based on co-localization of HIF1α binding, histone
marks, and HRE motifs, we named these enhancer/
promoter regions the 'promoter region' and the 'intronic
region', from 5′ upstream, respectively (Figure 3B). Con-
sidering this classification, we made a series of con-
structs for a subsequent reporter assay. From the 5′ end,
we named the HRE motifs 'Pro-HRE1' to 'Pro-HRE3',
and 'Int-HRE1' and 'Int-HRE2' (Figure 3B).
After luciferase activity was up-regulated in the pres-
ence of the promoter region under hypoxia (data not
shown), we made a further series of deletion mutant
constructs and HRE motif-mutated constructs to iden-
tify the hypoxia responsive sites (Table S3B in Additional
file 2). Using these mutated constructs and the promoter
and intronic regions, a luciferase assay was performed in
HUVECs under hypoxia (Figure 4A). The luciferase ac-
tivity of the promoter and intronic regions (shown in
the first line) was unchanged compared to the pro-
moter construct (shown in the second line) (Figure 4A).
Thus, the intronic region did not play an essential role
under hypoxia. Among the six constructs, the luciferase
activity under hypoxia was not significantly different
except for two constructs; the Pro-HRE1 deletion con-
struct and the HRE mutation 1 construct. However, the
HRE mutation 2 construct and HRE mutation 3 con-
struct were up-regulated to some extent. Thus, Pro-
HRE1 in the promoter region, which is located 2.0 kb
upstream of the TSS, was important for hypoxia re-
sponsive induction.Synergistic activation of ANGPTL4 transcription by
hypoxia and PPARβ/δ agonist in HUVECs and
identification of the functional PPAR-response element
As shown in Figure 2C, the induction of ANGPTL4 with
both stimuli was approximately five times higher than
that of hypoxia or the PPARβ/δ agonists alone, suggest-
ing that there is a synergistic activation mechanism be-
tween the two stimuli in HUVECs. Based on the finding
that the PPARβ/δ binding site was identified by ChIP-
seq at the third intron of ANGPTL4 (Figure 3C), where
functional HIF1α binding sites had already been identified
(Pro-HRE1 in Figure 3B), a reporter assay was carried out
using constructs containing the two essential units, the pro-
moter region, which is important for HIF1α stimulation,
and the intronic region, which is utilized for PPARβ/δ sig-
naling. As shown in Figure 4B, the activity of this construct
was greater than up-regulation from a single stimulus.
Thus, we considered the constructs shown in Figure 4B to
contain the units essential for synergistic activation, and we
made each of the mutated PPAR-response element (PPRE)
constructs shown in Figure 4C to identify the functional
PPRE. Reporter activity induction was compared to a non-
mutated control construct (Figure 4C, top), under four dif-
ferent conditions in three kinds of mutation construct.
Among them, the induction activity of the PPRE mutation
2 construct was suppressed significantly, and the induction
by PPARβ/δ agonist under normoxia was canceled. Even
under hypoxia, the effect of the PPAR agonist was dimin-
ished in this construct. These results suggested that all
of the three PPREs contributed to some extent to the
transcriptional enhancement, but PPRE 2 at the third in-
tron had the most profound effect on the regulation of
ANGPTL4 through PPARβ/δ agonist stimulation.
Stimuli induce the histone acetylation level of the
response elements and not the quantity of PPARβ/δ
binding to the third intron of ANGPTL4
As in the case of HIF1α recruitment, we originally hy-
pothesized that PPARβ/δ binding might be increased
in the course of the synergistic activation. Thus, we ana-
lyzed PPARβ/δ binding by ChIP-seq under four condi-
tions: no stimulation (DMSO+normoxia), PPARβ/δ agonist
stimulation (GW501516 + normoxia), hypoxia (1% O2 +
DMSO), and both PPARβ/δ agonist and hypoxia (GW50
1516 + 1% O2) for 24 hours. Unexpectedly, the locations
and distribution patterns of the PPARβ/δ binding (shown
in red) to ANGPTL4 did not change under the four condi-
tions (Figure 3C). Furthermore, the quantity of PPARβ/δ
binding to ANGPTL4 was compared by ChIP-PCR using
primers of the PPARβ/δ binding site at the third intron
of ANGPTL4 (Figure 3C; the primers for ChIP-PCR
are listed in Table S3C in Additional file 2), and the
level of PPARβ/δ binding under the four conditions




Figure 4 (See legend on next page.)
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Figure 4 Identification of the functional HRE and PPAR-response element on ANGPTL4, the quantity of PPARβ/δ binding to the third
intron of ANGPTL4 and histone acetylation level of the response elements. (A) Reporter assay with HRE mutations in intronic regions in
HUVECs. HUVECs were transfected and stimulated as shown in Material and methods. The reported HREs in the promoter and intronic region
located in constructs and shown by the blue arrows with numbers. (B) HUVECs were transfected with the construct containing known
PPAR-response elements (PPREs; red arrows in upper panel) and were stimulated with the PPARβ/δ agonist GW501516 (100 nM) and/or hypoxia
(1% O2) for 24 hours. Comparison was done between the indicated conditions. (C) Reporter assay for PPRE mutations. Cells were transfected with
each construct and stimulated with the PPARβ/δ agonist and/or hypoxia for 24 hours (as above). The reported PPREs are shown by the red
arrows with numbers. Comparison was with the untreated condition, and #P < 0.05 compared to the hypoxic condition. (D) ChIP-PCR of PPARβ/δ
under the four conditions. Location of primers is shown in Figure 3C. (E) ChIP-PCR of H3K27ac under the four conditions around the PPARβ/δ
binding site. Primers were designed for an upstream region close to the PPARβ/δ binding site at the third intron of ANGPTL4 (Figure 3E). (F)
ChIP-PCR of H3K27ac under the four conditions around the HIF1α binding site. Primers were designed for a downstream region close to the
HIF1α binding site 2 kbp upstream of the TSS (blue open arrow in Figure 3E). Primers for ChIP-PCR are listed in Table S5 in Additional file 2.
Comparison was with normoxia-DMSO sample or between indicated pairs. Data (mean ± standard deviation) are representative of three (A to C),
or two (D and F) independent experiments with similar results. ***P < 0.001, **P < 0.01, *P < 0.05; n.s., not significant.
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without any distribution change, and to test this notion,
we determined whether the activity of the enhancer was
affected. Previously, CBP/p300-mediated H3K27 acetyl-
ation in PPARβ/δ-dependent transcription was reported
[25], so we evaluated the intensity of H3K27ac, a marker
of enhancer activity. First, ChIP-seq analysis using an
anti-H3K27ac antibody was performed under the four
conditions and its distribution patterns on a genome-
wide scale were analyzed. In general, the number of
acetylation sites was increased by any of the forms of
stimulation by 12 to 13%, but its whole genome distribu-
tion patterns did not change significantly under the dif-
ferent conditions (Figure S10 in Additional file 1).
Approximately 70% of the H3K27ac was found at the
genes under all the conditions. In detail, 4% of H3K27ac
was located in an upstream region, 7% at the TSS, 6 to
7% in the 5′ UTR, 15 to 16% in the first intron, 23 to
24% in other introns, 5% in exons, 1% in the 3′ UTR
and 4 to 5% in downstream regions.
In terms of ANGPTL4, consistent with the general ten-
dency, the binding distribution of H3K27ac in ANGPTL4
did not change depending on the conditions (Figure 3D),
but the intensity of H3K27 acetylation did change with
the different types of stimulation. To compare this quan-
titatively, we performed ChIP-PCR using the primers de-
signed for the HRE and PPRE sites (the primers for
ChIP-PCR are listed in Table S3C in Additional file 2).
The level of H3K27 acetylation around the functional
PPRE (the site indicated with the open red arrow in
Figure 3E) was 3.7 times more enhanced by the PPARβ/δ
agonist, which is consistent with the ChIP-seq data
(Figure 4E). Surprisingly, however, even with hypoxic
stimulation, the acetylation level around PPRE was
3.0-fold up-regulated, and 5.3-fold induction was ob-
served with a combination of hypoxia and PPAR agon-
ist (Figure 4E). The same phenomenon was observed
around the functional HRE (Figure 4F). The level of
H3K27 acetylation around the HRE (the site indicatedwith the open blue arrow in Figure 3E) was 4.2 times
more enhanced under hypoxia. In addition, the acetyl-
ation around HRE was 2.3 times increased even with
the PPARβ/δ agonist alone, and 6.4 times with the
combination of stimuli (Figure 4F). These results sug-
gest that hypoxia and PPARβ/δ together cross-enhance
the intensity of the TF-bound enhancer sites.
HIF1α and PPARβ/δ change the chromatin conformation
in the ANGPTL4 locus
To dissect the molecular mechanism by which the two
different signaling cascades communicate with each other,
and with the intention of providing a physical basis for the
phenomenon, we considered the possibility that a change
in chromatin conformation might participate in the cross-
talk, since the main role of the enhancer is to form a chro-
matin loop through spatial proximity with the TSS [4,27].
To evaluate the proximity frequency of the two response
sites (HRE and PPRE) under the four different conditions,
quantitative chromatin conformation capture (3C) assay
was performed. As shown in Figure 5A, the functional
HRE (blue arrow) and PPRE (red arrow) are separated by
approximately 5.3 kb, and to perform the 3C assay, we
chose Sau3AI, a four base pair cutter, for DNA fragmenta-
tion. The primers and TaqMan probes for the 3C target
analysis were designed using both of the fragments con-
taining the functional HRE or PPRE (Figure 5A; and Table
S3D in Additional file 2). Figure 5B shows the results of
the TaqMan-3C assay, including the target locus shown
with the red circle in Figure 5A. Except for the target re-
gion, no increased interaction was observed. In the case of
either stimulation, compared with the control condition of
normoxia and DMSO (green versus red or blue lines in
Figure 5B), the frequency of crosslinking between the
HRE and PPRE was increased. The same crosslinking fre-
quency was observed for the combination of hypoxia and
PPARβ/δ agonist (Figure 5B, black line). These results
suggest that both of the single stimulations brought one






Figure 5 Chromatin conformation was changed at the ANGPTL4 locus by HIF1α and PPARβ/δ. (A) Schematic diagram of the ANGPTL4
gene locus and 3C experimental settings. The colored circles show the position of anchor primers and TaqMan probes (red for target anchor,
blue for control anchor). Arrowheads show the positions of primers. The digestion sites of Sau3AI are shown with the generated fragments
below. The distance from the TSS of ANGPTL4 is shown at the bottom with the primer name. The functional HRE and PPRE are shown with blue
and red arrows. The genomic location on the chromosome based on the hg18 build is shown at the top. (B) 3C assays based on HRE fragment.
Anchor primer and TaqMan probe were designed on HRE fragment and the other primers were designed for analyzing the crosslinking
frequency of the HRE and the other fragments (Figure 5A). HUVECs were treated with four conditions, then the relative frequencies were
compared among them. (C,D) 3C assays based on the control 1 (C) and control 2 (D) fragments. Anchor primer and TaqMan probe were
designed on the fragment located 4 kb upstream of the TSS (C1), and on the fragment located 6 kbp downstream of the TSS (C2). The other
primers are the same as in (B). To compare the data properly, the relative frequency data under dual stimulations in (B) are shown by the dotted
line. Primers for 3C experiments (B-D) are shown in Table S3D in Additional file 2 and the locations of primers are shown in Figure 5A. (E) 3C
assay of the target motif (HRE and PPRE) using siRNA against HIF1α and/or PPARβ/δ. HUVECs were transfected with siRNAs and, 48 h later,
stimulated for 24 hours. (F) ChIP-seq analysis (RNA polymerase II) of ANGPTL4. Data (mean ± standard error of the mean) are representative of
three independent experiments with similar results (B-E).
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ucts were directly sequenced and the conjunction of
the HRE and PPRE fragments mediated by the restric-
tion site was confirmed (Figure S11 in Additional file 1).
To see the specificity of the looping between HRE
and PPRE, we also performed a TaqMan-3C assay with
two different control anchor primers (blue circles in
Figure 5A). Figure 5C shows the results with the anchor
primer at the fragment located -4 kb from the TSS
of ANGPTL4, and Figure 5D shows these using theprimers 6 kb downstream of the TSS of ANGPTL4.
In Figure 5C, the relative crosslinking frequencies be-
tween P2 (TSS-8 kb) and control anchor region 1 (C1;
TSS-4 kb) were slightly increased under the stimula-
tions, but no looping was observed between C1 and the
PPRE (P5). Similarly, no increased relative crosslinking
frequency was observed between control anchor region
2 (C2) and the PPRE (P5), as expected. These results
support that the looping between the HRE and PPRE
specifically occurs upon stimulation.
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quires the observed chromatin conformational change at
the ANGPTL4 locus, we treated cells with siRNA against
HIF1α and/or PPARβ/δ and performed quantitative 3C
assays under stimulation with both hypoxia and the
PPARβ/δ agonist (Figure 5E). Though the effect of hyp-
oxia plus the PPAR agonist was measurable (1 versus 2
in Figure 5E), the frequency was changed by a reduction
of either PPARβ/δ (2 versus 3 in Figure 5E) or HIF1α (2
versus 4 in Figure 5E) or of a combination of both fac-
tors (2 versus 5 in Figure 5E), supporting the notion that
HIF1α and/or PPARβ/δ are involved in chromatin loop
formation at the HRE and PPRE of the ANGPTL4 locus.
Additive effect on active RNA polymerase II recruitment
by HIF1α and PPARβ/δ
The 3C data (Figure 5B-E) strongly suggest that a higher
frequency of spatial proximity of two response elements is
beneficial to synergistic induction of ANGPTL4 by hyp-
oxia and the PPARβ/δ agonist in HUVECs (Figure 2C).
The luciferase activity result for the ANGPTL4 construct
(Figure 4B) also supports this notion. To confirm the con-
formation change is associated with more efficient recruit-
ment of active RNA polymerase II (Pol II), ChIP-seq
analysis using anti-phospho C-terminal domain (CTD) of
Pol II under the four conditions was performed. As shown
in Figure 5F, more Pol II was recruited to the TSS of
ANGPTL4 with either hypoxic (second line in Figure 5F)
or PPARβ/δ agonist stimulation (third line in Figure 5F).
Furthermore, the highest degree of Pol II distribution in
ANGPTL4 was observed under the dual stimulation
(fourth line in Figure 5F) and this phenomenon was con-
firmed by ChIP-PCR of Pol II (Figure S12 in Additional
file 1). These findings confirm that the conformational
change caused by the dual stimulation resulted in additive
localization of Pol II in the target motif.
Discussion
The angiopoietin/angiopoietin-like gene family encodes a
glycosylated, secreted protein with a fibrinogen carboxy-
terminal domain. In vascular cells, the angiopoietins act as
major regulators of angiogenesis and vascular permeability
through binding to the Tie-2 receptor [7]. Angiopoietin-
like proteins (ANGPTL1 to 7) share structural and func-
tional properties with angiopoietins, but do not bind to
the Tie-2 receptor [28]. This study shows that, under hyp-
oxia and PPARβ/δ stimulation, ANGPTL4 was intensely
expressed (Figure 2C; Table S1 in Additional file 2). These
results confirm the previous finding that ANGPTL4 is
highly induced by hypoxia in endothelial cells [29,30]. Full
length ANGPTL4 exists as an oligomeric complex, and it
can be cleaved in vivo to release the two domains, result-
ing in the presence of both the full-length and cleaved
forms in plasma. The amino-terminal coiled-coil domaininhibits lipoprotein lipase (LPL) activity and increases
plasma triglycerides [31], while the carboxy-terminal
FBG-like domain (cANGPTL4) is associated with the
integrity of endothelial cells [32]. Since migration of
HUVECs was synergistically enhanced by the two stimuli
(Figure 1), which induced ANGPTL4, our findings imply
that increased carboxy-terminal domain activity might
participate by disrupting endothelial junctions by an effect
on integrins, as was reported previously [33]. In contrast,
however, ANGPTL4-deficient mice displayed decreased
vascular integrity in the retina [34] and heart [35]. Fur-
thermore, administration of recombinant ANGPTL4 was
effective as a treatment for acute myocardial infarction
because it counteracts the increase in permeability ob-
served in re-perfused acute myocardial infarction [35].
Although leukocyte immunoglobulin-like receptor B2
(LILRB2) was identified as an agonist for other members
of the ANGPTL family, the agonist for ANGPTL4 is still
unidentified [36]. Furthermore, the PPARβ/δ-ANGPTL4
pathway was shown to be involved in tumor cell invasion
[37]. Therefore, the role of ANGPTL4 in the inflammatory
response in vivo needs to be interpreted, taking into con-
sideration communication with other cell types involved
in angiogenesis or wound healing.
One of the transcriptional regulators of ANGPLT4 is
HIF1α, and this TF is known to be recruited to target
genes immediately after hypoxic stimulation [4]. Another
transcription regulator of ANGPTL4 is PPARβ/δ, which
belongs to the nuclear receptor superfamily as a subclass
of TFs. In general, gene induction by nuclear receptors
only happens when a ligand (agonist) is present. PPAR
ligands (agonists) change the PPARs’ structures, result-
ing in modulation of receptor properties [38]. However,
an agonist-independent high basal activity of PPARs has
also been reported [39]. In addition, DNA binding of the
thyroid receptor, which belongs to the nuclear receptor
family (type II nuclear receptor), was reported to not be
agonist-dependent [40]. Thus, the recruitment of nuclear
receptors is not strictly essential to agonist-dependent
gene induction. PPARs are also type II nuclear receptors,
and fatty acids, triglycerides, prostacyclin, and retinoic
acid are known as endogenous agonists for PPARβ/δ
[41]. In our results, the quantity of PPARβ/δ binding at
the ANGPTL4 locus was not changed under the four
conditions we tested (Figure 4D), confirming the notion
that PPARβ/δ binds to DNA irrespective of the presence
of its exogenous agonists. In the absence of agonists,
nuclear receptors function by utilizing co-repressors,
which maintain the nuclear receptors in a repressed
state, and these co-repressors are dismissed when the
co-activators are recruited following agonist stimulation
[25,42]. Co-activators have been reported in the case of
certain TFs, including HIF1α [43], and the involvement
of CBP/p300 was linked to histone acetylation [44]. As
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was also linked to CBP/p300-mediated H3K27ac [25].
Taken together, the generation of H3K27ac is a common
histone modification shared by the PPARβ/δ and HIF1α
signaling cascades, and analyses of the H3K27ac distri-
bution profile allowed us to trace the activity of these
two transcriptional regulators.
We compared the ChIP-seq data for HIF1α and PPARβ/
δ with those for H3K4me3 as a marker of promoter activity
[21], and H3K4me1 [22] in addition to H3K27ac [23-25] as
markers of enhancer activity (Figure 3A,D). The potentially
active enhancers based upon the co-localization of both
TFs and histone modifications were validated by luciferase
assays (Figure 4). The PPAR binding region observable
near ANGPTL4 by ChIP-seq in HUVECs was consistent
with those reported previously in myofibroblasts [42]. The
function of the binding region as an enhancer was sup-
ported by reporter assay in endothelial cells, as was re-
ported previously in adipocytes [45] and myofibroblasts
[46]. To confirm this, we performed more assays using
PPRE deletion constructs. The intensity of H3K27ac at the
functional PPRE was enhanced by PPAR agonist addition,
but also cross-enhanced by hypoxia (Figure 4E). H3K27ac
at the HRE was increased not only by hypoxia, but also by
the PPAR agonist (Figure 4F). These findings led us to the
notion that the two elements might be located in spatial
proximity of one another. Since H3K27ac is acetylated
mainly by CBP/p300 [25], histone acetyltransferases might
be recruited to both the HRE and PPRE following each
stimulus. However, there is no known mechanism to bring
CBP/p300 to PPREs or vice versa after hypoxia. One ex-
planation for this may be co-instantaneous chromatin con-
formational change, which could bring about a closer
spatial proximity of the HRE and PPRE, and this was
indeed shown to be the case by TaqMan-3C assay
(Figure 5B-E). As reported previously, this can result in
loop formation between the two elements [47]. Therefore,
our data suggest the existence of complexes composed of
TFs and histone acetyltransferases.
In yeast [48] and mammalian cells [49,50], a mediator
complex connects enhancers and core promoters through
chromatin conformational changes in combination with
cohesin. Further conceptualization of the complexity of
transcription initiation postulates the existence of 'tran-
scription factories' [51-53] containing a variety of compo-
nents, including active Pol II, histone variants, and histone
modifiers. As was shown in the context of inflammatory
stimulation, specialized factories are supposed to contain
appropriate TFs, in this case NF-κB [45]. Likewise, special-
ized factories for hypoxia might contain HIF1α and for
the PPAR agonist might contain PPARβ/δ, which connects
factories and enhancers. Therefore, it is plausible that the
HIF1α-driven factory would come into contact with the
HRE in the 5′ upstream region of the TSS and thenchange chromatin conformation to bring the HRE closer
to the transcribed region of ANGPTL4 (Figure 5B). This
would result in spatial proximity of CBP/p300 and the
PPRE, causing histone acetylation of the PPRE (Figure 4E).
In contrast, acetylation of the HRE upon PPARβ/δ agonist
stimulation (Figure 4F) is difficult to explain unless the
transcription complex recruited to the PPRE changes the
chromatin conformation such that the HRE and PPRE
come into closer proximity. As shown in Figure 5B, this
spatial proximity between the HRE and PPRE was ob-
served in the case of each stimulus individually or both
stimuli together using the 3C method. Considering the
cross-acetylation of histone 3 lysine 27 (Figure 4E,F), this
chromatin conformation change might suggest a special-
ized transcription factory of HIF1α and agonist bound
PPARβ/δ. Also, this conformational change might enable
one enhancer to be activated by another stimulus, and this
may be the mechanism responsible for synergistic activa-
tion of common target genes by two kinds of transcription
regulators (Figure 6). Knocking down one factor (either
PPARβ/δ or HIF1α) under the dual stimulation condition
resulted in greatly reduced interaction between the HRE
and PPRE, even though the other factor is still intact
(Figure 5E). It could be speculated that a specialized
factory without a specific TF not only loses its function
but also perturbs other native transcription complexes,
presumably by taking over Pol II or by blocking appro-
priate recruitment of another specialized factory, and
this model should be tested in the near future. Al-
though the details of the components and dynamics of
PPAR-dependent factories needs to be elucidated, these
findings might support the existence of specialized
transcription factories, as predicted.
To the best of our knowledge, this is the first report of
two different TFs cooperating in transcriptional regula-
tion through the conformational change of the target
gene. Nuclear receptors have the potential to crosstalk
with various other sequence-specific DNA-binding TFs
at adjacent sites, resulting in a modification of gene ex-
pression. The existence of crosstalk between different
TFs has already been reported, and some of the mecha-
nisms have been elucidated [54]. 'Pioneer TFs' such as
forkhead box A1 (FoxA1) and estrogen receptor alpha
(ERα) provide an example of the interaction mechanisms
[55]. The synergistic regulation of ANGPTL4 by trans-
forming growth factor (TGF)β and PPARβ/δ was re-
ported using a human prostatic stromal myofibroblast
cell line (WPMY-1), and looping between the TGFβ re-
sponse element enhancer and PPAR-response element
enhancer was in fact postulated previously, although it
was not confirmed [46]. The development of 3C tech-
nology enabled us to demonstrate the conformational
proximity of the two response elements [26] under dif-
ferent conditions. Our findings imply that a chromatin
  
Figure 6 Schematic diagram of synergistic transcription induction mediated by spatial proximity. Upper part shows the ANGPTL4 locus,
including the HRE, TSS, and PPRE. PPARβ/δ sits at the PPRE before stimulation. Left: under hypoxia, acetyltransferases approach the HRE locus by
virtue of HIF1α binding to the HRE. ANGPTL4 assumes a loop formation in order to bring the HRE closer to the PPRE. Although the PPRE is not a
direct target of HIF1α, this conformation causes acetylation of the PPRE. Right: under PPAR ligand (agonist) stimulation, PPARβ/δ's location does
not change but it is chemically modified to the active form. Presumably by virtue of a cofactor of PPAR, the PPRE comes closer to the HRE,
resulting in acetylation of the HRE. Center: under dual stimulation, the HRE and PPRE move closer to each other, causing additive acetylation of
both regions, and increased amounts of Pol II might be loaded at the TSS, possibly resulting in synergistic transcription activation and crosstalk.
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activation that takes place with different stimuli.
Conclusions
Chromatin conformation capture and ChIP studies clearly
identified that the mechanism of synergistic ANGPTL4 ac-
tivation comprises DNA looping and histone modification.
The mechanism of synergistic ANGPTL4 activation pro-
vides an important clue to how different types of stimula-
tion interact with each other.
Materials and methods
Cell culture
Cells were maintained at 37°C in a humidified 5% CO2 in-
cubator. Primary culture of HUVECs was prepared and
maintained in EGM-2 MV (Lonza, Basel, Switzerland) con-
taining 5% FBS. Experiments under hypoxic conditions(1% O2) were performed in a hypoxic cultivation incubator
(Juji Field Co. Ltd, Tokyo, Japan). The cells used in the ex-
periments were from passage 6 or less.
Chemicals and antibodies
GW501516 (GlaxoSmithKline, London, UK) was used as
a PPARβ/δ agonist at a concentration of 100 nM. An
anti-PPARβ/δ monoclonal antibody was produced in-
house [56]. Mouse monoclonal IgG-Y9705 against human
PPARβ/δ was raised in our laboratory by immunizing mice
with recombinant baculovirus displaying gp64-fusion pro-
teins containing amino acids 2 to 41 of human PPARβ/δ.
The anti-HIF1α (NB 100-134; Novus Biologicals, Littleton,
CO, USA), anti-H3K4me3 (ab8580; Abcam, Cambridge,
UK) antibodies and anti-ANGPTL4 (ab47046; Abcam)
were purchased. The anti-H3K27ac, anti-H3K4me1 [57]
and anti-panphospho Pol II antibodies were provided by
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in press). Recombinant ANGPTL4 (P01) was from Abnova
(Taipei, Taiwan).
Chromatin immunoprecipitation
Two million HUVECs were plated on a 15-cm culture
plate. HUVECs were maintained in EGM-2 MV contain-
ing 5% FBS and the cells were stimulated with hypoxia
and/or PPARβ/δ agonist for 24 hours. The cells were
crosslinked for 10 minutes using 1% paraformaldehyde at
the appropriate time thereafter. After neutralization using
0.2 M glycine, cells were recollected, resuspended in SDS
lysis buffer (10 mM Tris-HCl, 150 mM NaCl, 1% SDS,
1 mM EDTA; pH 8.0) and fragmented by sonication
(Branson, Danbury, CT, USA; 10 minutes). Samples were
stored at -80°C before use. To perform ChIP, antibodies
against PPARβ/δ, H3K27ac and Pol II were used in com-
bination with magnetic beads (Life Technologies/Thermo
Fisher Scientific, South San Francisco, CA, USA). Pre-
pared DNA was quantified using Qubit (Life Technolo-
gies/Thermo Fisher Scientific) and more than 10 ng of
DNA was processed, as described below. The ChIP primer
sequences are listed in Table S3C in Additional file 2.
ChIP-seq
All of the protocols for Illumina/Solexa sequence prep-
aration, sequencing and quality control were provided
by Illumina. Sequences were aligned using human gen-
ome NCBI Builder 36 (UCSC hg18) as the reference
genome. Non-immunoprecipitated DNA (input DNA)
was used as a negative control to define non-specific
binding. All uniquely mapped sequences were analyzed
by Quantitative Enrichment of Sequence Tags (QuEST)
2.4 software using the default parameters (KDE band-
width = 30 bp, region size = 300 bp, ChIP seeding fold
enrichment = 30, ChIP extension fold enrichment = 3,
ChIP-to-background fold enrichment = 3 for PPARβ/δ
and HIF1α, KDE bandwidth = 60 bp, region size =
600 bp, ChIP seeding fold enrichment = 30, ChIP exten-
sion fold enrichment = 3, ChIP-to-background fold
enrichment = 3 for Pol II, KDE bandwidth = 100 bp, re-
gion size = 1000 bp, ChIP seeding fold enrichment = 30,
ChIP extension fold enrichment = 3, and ChIP-to-
background fold enrichment = 3 for H3K27ac, H3K4me1
and H3K4me3) [20]. WIG files were generated with
QuEST, which were subsequently used for visualization
purposes and for obtaining the average signal profiles.
These signals were visualized using Integrated Genome
Browser software [58] with normalized profile wig files
calculated by QuEST.
Mapping of ChIP-seq reads
All ChIP-seq analyses were performed using a GAII
(Illumina). We duplicated ChIP-seq procedures (FigureS13). For PPARβ/δ, in total 36,607,827 and 36,864,223
(normoxia-DMSO), 38,936,258 and 35,654,581 (normoxia-
PPARβ/δ), 36,760,328 and 43,029,618 (hypoxia-DMSO),
and 35,058,306 and 43,474,951 (hypoxia-PPARβ/δ) reads
were aligned and 76.7% and 78.8% (normoxia-DMSO),
77.6% and 53.7% (normoxia-PPARβ/δ), 74.0% and 79.0%
(hypoxia-DMSO), and 78.8% and 79.4% (hypoxia-PPARβ/
δ) of the total reads were aligned uniquely to the non-
repeating human genomic sequence. For H3K27ac, out of
a total of 36,530,846 and 41,560,945 (normoxia-DMSO),
37,346,766 and 44,268,585 (normoxia-PPARβ/δ), 38,316,199
and 38,228,969 (hypoxia-DMSO), 36,900,687 and 41,208,
985 (hypoxia-PPARβ/δ) sequence reads, 83.0% and 85.7%
(normoxia-DMSO), 85.7% and 85.3% (normoxia-PPARβ/δ),
85.8% and 84.2% (hypoxia-DMSO), and 84.6% and 84.8%
(hypoxia-PPARβ/δ) were uniquely mapped. For Pol II,
34,732,013 and 41,475,510 (normoxia-DMSO), 28,155,220
and 42,030,082 (normoxia-PPARβ/δ), 31,755,951 and 43,
544,244 (hypoxia-DMSO), and 31,015,638 and 41,895,797
(hypoxia-PPARβ/δ) reads were totally aligned and 81.5%
and 80.8% (normoxia-DMSO), 83.0% and 81.4% (nor-
moxia-PPARβ/δ), 83.1% and 81.4% (hypoxia-DMSO), and
83.3% and 81.5% (hypoxia-PPARβ/δ) of the total reads
were aligned uniquely to the non-repeating human gen-
omic sequence. Detailed information regarding HIF1α,
H3K4me1, H3K4me3 was provided previously [4].
Motif search
A de novo motif search was performed using MEME
(version 4.6.1) [59]. All the non-repetitive 100 bp se-
quences calculated by QuEST were used and analyzed.
The MEME parameters were 'distribution of motif oc-
currences; any number of repetitions, minimum motif
width; 6, maximum motif width; 30'. The Weblogo pro-
gram [60] was used to indicate the motifs. The E-value
is an estimate of the expected number of motifs with the
given log likelihood ratio for the random sequences.
Motif comparison
The enriched sequence was compared to the known
consensus TF motifs using TOMTOM (version 4.8.1)
with the motif databases JASPAR and UniPROBE [61].
The Tomtom web application compares an input DNA
motif to the elements of a database of known motifs
(and their DNA reverse complements). A list of the
matching motifs is shown, ranked by q-value. The q-
value is the minimum false discovery rate at which the
observed similarity would be deemed significant.
DNA microarray
HUVECs maintained with EGM-2 MV containing 5%
FBS were stimulated with hypoxia and/or the PPARβ/δ
agonist for 24 hours. Total cellular RNA was isolated
using an RNeasy Micro kit (QIAGEN, Hilden, Germany).
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arrays were performed according to the manufacturer’s in-
structions (Affymetrix, Santa Clara, CA, USA). Affymetrix
Genechip Human Genome U133 plus 2.0 arrays contain-
ing over 54,000 probe sets were applied. The expression
value for each mRNA was obtained by the robust multi-
array analysis (RMA) method. To analyze the expression
data at the genetic level, the intensity of the signal values
was summarized using Entrez Gene ID (normalized to
the 75th percentile). Then the gene set probes were fil-
tered on an expression (20.0 to 100.0) percentile. Genes
expressed at lower than the 20 percentile in all of the four
arrays were eliminated from the analyses. After excluding
the gene set probes that did not have gene symbols, the
remaining 21,089 genes were used for further analysis.
Hierarchical cluster analysis was performed using average
linkage and Pearson correlation as a measure of similarity.
All analysis was performed with GeneSpring GX 12.5
(Agilent Technologies, Santa Clara, CA, USA). Annota-
tion of the probe numbers and targeted sequences are
shown on the Affymetrix web page.
Binding motif estimation in silico
Motif estimation for the binding sites of PPARβ/δ was
performed using MatInspector, a software for identifica-
tion of TF binding sites provided by Genomatix (Munich,
Germany)
Luciferase reporter assay
Transfections were performed with Fugene HD (Roche,
Basel, Switzerland). Cells were transfected on 12-well
plates at 70 to 80% confluence in Opti-MEM (Life Tech-
nologies/Thermo Fisher Scientific) with 0.5 μg of plas-
mid. Cells were incubated for 24 hours in normal
growth medium, then the stimulation was initiated. Lu-
ciferase assays were performed 24 hours after stimula-
tion. Luciferase activity was calibrated with the Renilla
activity. The primers for the site-directed mutagenesis of
the HRE and PPRE motifs are shown in Table S3B in
Additional file 2.
Quantitative RT-PCR
Total cellular RNA was isolated using an RNeasy Micro
kit (QIAGEN). The cDNA was synthesized from 100 ng
of RNA using oligo (dT) primers and the Superscript
III kit (Life Technologies/Thermo Fisher Scientific).
qPCR was performed on a CFX96 real-time System
(BioRad, Hercules, CA, USA) for 45 cycles at an anneal-
ing temperature of 60°C. PCRs were carried out using
iQ SYBR Green Supermix (BioRad) and a primer con-
centration of 200 nM, following the manufacturer’s in-
structions. 18S rRNA was used as the normalizer. The
sequences of SYBR Green primers are listed in Table
S3A in Additional file 2.Western blotting
Protein samples were separated by 10% SDS-PAGE and
transferred electrophoretically onto nitrocellulose membranes
(Hybond-C; GE Healthcare UK Ltd, Buckinghamshire,
England). Membranes were blocked with 5% (w/v) nonfat
milk in phosphate-buffered saline containing 0.1% Tween
for 1 hour, incubated with antibodies for 1 hour, and de-
tected by chemiluminescence using West Dura extended
duration substrate (Thermo Fisher Scientific, Waltham,
MA, USA) according to the manufacturer’s protocol.Quantitative chromosome conformation capture assay
HUVECs were maintained in EGM-2 MV containing 5%
FBS, then the cells were stimulated with hypoxia and/or
PPARβ/δ agonist for 24 hours. The assay was performed
utilizing the TaqMan 3C Chromosome Conformation
Kit (EcoRI; Life Technologies/Thermo Fisher Scientific)
according to the manufacturer’s instructions, with cer-
tain modifications. Briefly, HUVECs were crosslinked
with 1% paraformaldehyde for 10 minutes. The reaction
was stopped by the addition of 125 mM glycine for 5 mi-
nutes. Nuclei were re-suspended with restriction enzyme
buffer. Samples were treated with 400 U of Sau3AI at
37°C for 16 hours. After enzyme digestion, the samples
were diluted with ligation buffer and treated with DNA
ligase at 16°C for 1 hour. Samples were finally reverse
crosslinked and purified. All primers and TaqMan
probes are shown in Table S3D in Additional file 2 and
the positions of the primers are shown in Figure 5A.
We used 50 ng of DNA for the 3C assay. In addition, to
normalize template loading, an input normalization
assay in the 3C kit was used according to the reported
protocol with some modification [62]. Two human
BAC clones (RP11-995 M24, RP11-978 J4) were used to
normalize the levels of 3C products that may have been
PCR amplified with different primer efficiencies, as
mentioned previously [62,63].Gene knockdown by siRNA
EGM-2 MV used for HUVEC culture was replaced with
Opti-MEM culture medium, and the cells were trans-
fected with stealth RNA interference for HIF1α (Life
Technologies/Thermo Fisher Scientific, HSS104774 and
HSS104775) and PPARβ/δ (Life Technologies/Thermo
Fisher Scientific, HSS108293 and HSS108294) at a con-
centration of 10 nM using Lipofectamine RNAiMax re-
agent (Life Technologies/Thermo Fisher Scientific). After
6 hours, the culture medium was changed back to EGM-2
MV. After another 24 hours, cells were stimulated with
hypoxia and/or the PPARβ/δ agonist. The knockdown ef-
ficiencies of HIF1α and PPARβ/δ were validated by qRT-
PCR (CFX96, BioRad) using the same primers described
above (Table S3A in Additional file 2).
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We plated 150,000 HUVECs in a 35 mm type I collagen-
coated culture plate (IWAKI, Asahi glass, Tokyo, Japan)
and incubated the cells under usual conditions for 48 hours.
After making a scratch in the cell monolayer using a 5 ml
serological pipette, EGM-2 MV was replaced with EBM-2
culture medium for Figure 1 or EGM-2 MV culture
medium for Figure S6 in Additional file 1, and then the
stimulation was initiated or recombinant ANGPTL4 was
added. The first image of the scratch was acquired at this
time. After 8 hours, an image was obtained at exactly the
same place as the first image. The images acquired for each
sample were analyzed quantitatively using the software
Image J (NIH) and the migration areas were calculated.
Statistical analysis
P-values were calculated using two-tailed unpaired Stu-
dent’s t-test. P < 0.05 was considered significant.
Availability of data
Data are available from the Gene Expression Omnibus
[64]. The ChIP-seq datasets are available at accession
numbers GSE38555 and GSE50144 and the microarray
analysis is accession GSE50378.
Additional files
Additional file 1: Figure S1. Scatter plot of the genes affected by
PPARβ/δ agonist or hypoxia treatment in endothelial cells. Figure S2.
Classification of the hierarchical entity tree for the samples. Figure S3.
Scatter plot of the genes induced by the PPARβ/δ agonist and/or
hypoxia. Figure S4. Real time PCR of ANGPTL4 with primers recognizing
intron-exon junctions. Figure S5. Western blotting of ANGPTL4 under
the four conditions. Figure S6. Endothelial cell migration is enhanced by
ANGPTL4. Figure S7. Genome-wide analysis of PPARβ/δ and/or hypoxia
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